¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antibody technology"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • circulating antibody
    Ç÷ÁßÇ×ü
  • cold antibody
    Àú¿ÂÇ×ü
  • complement-fixing antibody
    º¸Ã¼°áÇÕÇ×ü, µµ¿òü°áÇÕÇ×ü
  • complete antibody
    ¿ÏÀüÇ×ü
  • coprecipitation antibody
    µ¿¹ÝħÀüÇ×ü
  • cross-reacting antibody
    ±³Â÷¹ÝÀÀÇ×ü
  • cytolytic antibody
    ¼¼Æ÷¿ëÇØÇ×ü
  • cytophilic antibody
    ¼¼Æ÷ģȭÇ×ü
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼ºÇ×ü
  • cytotropic antibody
    ¼¼Æ÷ģȭÇ×ü
  • cell-associated antibody
    ¼¼Æ÷¿¬°üÇ×ü
  • cell-bound antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • cell-fixed antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • cellular antibody
    ¼¼Æ÷Ç×ü
  • chimeric antibody
    Ű¸Þ¶óÇ×ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • complete antibody
    ¿ÏÀüÇ×ü
  • coprecipitation antibody
    µ¿¹ÝħÀüÇ×ü
  • cross-reacting antibody
    ±³Â÷¹ÝÀÀÇ×ü
  • cytolytic antibody
    ¼¼Æ÷¿ëÇØÇ×ü
  • cytophilic antibody
    (¢¡cytotropic antibody) ¼¼Æ÷ģȭÇ×ü
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼ºÇ×ü
  • cytotropic antibody
    ¼¼Æ÷ģȭÇ×ü
  • diagnostic antibody
    Áø´Ü¿ëÇ×ü
  • divalent antibody
    À̰¡Ç×ü
  • enzyme labeled antibody
    È¿¼ÒÇ¥ÁöÇ×ü
  • fluorescent antibody
    Çü±¤Ç×ü
  • heat labile antibody
    ¿­¹Î°¨Ç×ü
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü
  • hemolytic antibody
    ¿ëÇ÷Ç×ü
  • heterocytotropic antibody
    ÀÌÁ¾¼¼Æ÷ģȭÇ×ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antibody feedback mechanism
    Ç×üµÇ¸ÔÀ̱â±âÀü.
  • antibody formation
    Ç×üÇü¼º(ù÷ô÷û¡à÷).
  • antibody forming cell
    Ç×ü»ý»ê¼¼Æ÷(ù÷ô÷ßæß§á¬øà).
  • antibody half-life
    Ç×ü¹Ý°¨±â(ù÷ô÷ÚâÊïÑ¢).
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody production
    Ç×ü»ý»ê(¡­ßæß§).
  • antibody removal
    Ç×üÁ¦°Å
  • antibody response
    Ç×ü¹ÝÀÀ(¡­Úãëë).
  • antibody screening cells
    Ç×ü¼±º°Ç÷±¸
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • antibody structure
    Ç×ü±¸Á¶(¡­Ï°ðã).
  • antibody synthesis =a. production
    Ç×ü»ý»ê, Ç×üÇÕ¼º.
  • antibody titer
    Ç×ü°¡(ù÷ô÷ʤ).
  • antibody to HBc ag
    B Çü °£¿°ÇÙ½ÉÇ׿ø¿¡´ëÇÑ Ç×ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antibody structure
    Ç×ü±¸Á¶(¡­Ï°ðã).
  • antibody synthesis =a. production
    Ç×ü»ý»ê, Ç×üÇÕ¼º.
  • antibody titer
    Ç×ü°¡(ù÷ô÷ʤ).
  • antibody to HBc ag
    B Çü °£¿°ÇÙ½ÉÇ׿ø¿¡´ëÇÑ Ç×ü
  • antibody to HBe ag
    B Çü °£¿°¿ÜÇÇÇ׿ø¿¡´ëÇÑ Ç×ü
  • antibody to HBs ag
    B Çü °£¿°Ç¥¸éÇ׿ø¿¡´ëÇÑ Ç×ü
  • antibody to HD ag
    HD Ç׿ø¿¡´ëÇÑ Ç×ü
  • antibody to histidyl tRNa synthetase
    È÷½ºÆ¼µô tRNa ÇÕ¼ºÈ¿¼Ò¿¡ ´ëÇÑ Ç×ü
  • antibody to thyroglobulin
    Ƽ·Î±Û·ÎºÒ¸°<°©»ó¼±±Û·ÎºÒ¸°>¿¡ ´ëÇÑ Ç×ü
  • antibody to thyrotropin
    °©»ó¼±ÀÚ±ØÈ£¸£¸ó¿¡ ´ëÇÑ Ç×ü
  • antibody transfer
    Ç×üÀÌÀÔ(¡­ì¹ìý).
  • antibody unit
    Ç×ü´ÜÀ§(ù÷ô÷Ó¤êÈ).
  • antibody unit
    Ç×ü´ÜÀ§(ù÷ô÷Ó¤êÈ).
  • antibody unit
    Ç×ü´ÜÀ§(ù÷ô÷Ó¤êÈ).
  • antibody valence
    Ç×ü°áÇÕ°¡(¡­Ì¿ùêʤ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • hybrid antibody
    Æ¢±â Ç×ü(ù÷ô÷)
  • idiotypic antibody
    °³Ã¼Æ¯ÀÌÇü(ËÁô÷÷åì¶úþù÷ô÷)
  • immune antibody
    ¸é¿ª Ç×ü(Øóæ¹ù÷ô÷)
  • incomplete antibody
    ºÒ¿ÏÀü Ç×ü(ÝÕèÇîïù÷ô÷)
  • indirect fluoresccnt antibody technique
    °£Á¢ Çü±¤Ç×ü¼ú(ÊàïÈû«ÎÃù÷ô÷âú)
  • isophile antibody
    È£µ¿Á¾ Ç×ü(û¿ÔÒðúù÷ô÷)
  • low-order antibody
    ÀúÂ÷Ç×ü(î¸ó­ù÷ô÷)
  • multivalent antibody
    ´Ù°¡Ç×ü(Òýʤù÷ô÷)
  • natural antibody
    ÀÚ¿¬Ç×ü(í»æÔù÷ô÷)
  • nonagglutinating antibody
    ºñÀÀÁýÇ×ü(Þªëêó¢ù÷ô÷)
  • nonprecipitating antibody
    ºñħÀü Ç×ü(ÞªöØîþù÷ô÷)
  • precipitating antibody
    ħ°­ Ç×ü(öØË½ù÷ô÷)
  • radioactive antibody test
    ¹æ»ç¼º Ç×ü ½ÃÇè(°ËÁ¤)(Û¯ÞÒàõù÷ô÷ãËúÐ(ËþïÒ))
  • reaginic antibody
    ·¹¾ÆÁø Ç×ü(ù÷ô÷)
  • theory of antibody formation
    Ç×üÇü¼º ÀÌ·Ð (ù÷ô÷û¡à÷×âÖå)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
PCA para-chloramphetamine; parietal cell antibody; passive cutaneous anaphylaxis; patient care assistant...
TA alkaline tuberculin; arterial tension; axillary temperature; tactile afferent; Takayasu arteritis; t...
ACTS acute cervical traumatic sprain or syndrome; advanced communication technology satellite; American C...
ARC-ST Accreditation Review Council for Educational Programs in Surgical Technology
ASMT American Society for Medical Technology
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
aCL Anti-cardiolipin antibody
ACA Anti-centromere antibody
AGA Anti-gliadin antibody
ANCA Anti-neutrophil cytoplasm antibody
ANA Anti-nuclear antibody
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • HIV antibody
    HIV Ç×ü
  • humoral antibody
    ¾×¼º Ç×ü
    ü¾×¼º ¸é¿ªÀ» ´ã´çÇÏ´Â ¸é¿ª ±Û·ÎºÒ¸°. ³× °³ÀÇ
  • humoral antibody
    ¾×¼º Ç×ü, ü¾×¼º Ç×ü, ü¾× Ç×ü
  • humoral cytotoxic antibody
    ü¾×¼º ¼¼Æ÷ µ¶¼º Ç×ü
  • immunofluorecent antibody test
    ¸é¿ª Çü±¤ Ç×ü °Ë»ç¹ý
  • intrinsic factor antibody
    ³»Àμº ÀÎÀÚ Ç×ü
  • Jo-1 antibody
    Jo-1 Ç×ü
  • labelled antibody
    Ç¥Áö Ç×ü
    ±× ¿òÁ÷ÀÓÀ̳ª À§Ä¡¸¦ ¾Ë±â À§ÇØ ¶óº§¸µÇÑ Ç×ü.
  • Langmuir expression in drug-antibody binding
    ¾à¹°-Ç×ü °áÇÕ¿¡¼­ÀÇ ¶û¹¿¸£ Ç¥Çö
  • leukocyte antibody
    ¹éÇ÷±¸ Ç×ü
  • monovalent antibody
    Àϰ¡ Ç×ü
  • multivalent antibody
    ´Ù°¡ Ç×ü
  • panel in antibody identification
    Ç×ü µ¿Á¤ ÆÐ³Î, Ç×ü µ¿Á¤¿ë ÆÐ³Î
    Ç×üÀÇ »ý¼º ¿©ºÎ¸¦ ¾Ë¾Æº¸±â À§ÇÑ ÆÐ³ÎÆÇ.
  • percent reactive antibody test
    ÆÛ¼¾Æ® ¹ÝÀÀ Ç×ü °Ë»ç
  • polyclonal antibody
    ´ÙŬ·Ð¼º Ç×ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
antiparietal cell antibody <immunology> A serologic blood test which measures the presence of antibodies to gastric parietal cells.
Less than 2% of the general population will be antibody positive although this can be higher in the elderly.
Approximately 90% of individuals with pernicious anaemia will be antibody positive. A positive result may also be seen in atrophic gastritis, gastric ulcer, thyroid disease, iron deficiency anaemia and diabetes.
(13 Jan 1998)
antiphospholipid antibody <immunology, syndrome> An uncommon disorder that is characterised by hypercoagulability due to the presence of antibodies against phospholipids.
These patients exhibit a tendency for recurrent and life-threatening thrombosis and embolic events (for example stroke). Individuals with antiphospholipid syndrome also have an increased tendency toward deep venous thrombosis, myocardial infarction and spontaneous abortions in females.
Antiphospholipid syndrome may be seen by itself or in association with other autoimmune illnesses (for example lupus) or with some infections.
Treatment includes long-term heparin and warfarin.
(13 Jan 1998)
antiphospholipid antibody syndrome <syndrome> An immune disorder characterised by the presence of abnormal antibodies in the blood associated with certain medical conditions including abnormal blood clotting, migraine headaches, premature miscarriage, and low blood platelet counts (thrombocytopenia).
(12 Dec 1998)
antithyroglobulin antibody <endocrinology, immunology> A serologic blood test which measures the antithyroglobulin antibodies in the blood. Thyroglobulin is a protein found in thyroid tissue. It is the source of thyroid hormones in the body.
The presence of antibodies to this protein can result in decreased thyroid gland function. A negative assay is considered normal.
Conditions where the assay may be positive include: lupus, rheumatoid arthritis, Hashimoto's thyroiditis, thyrotoxicosis, hypothyroidism, thyroid cancer, myxoedema, Sjogren's syndrome and autoimmune haemolytic anaemia.
(13 Jan 1998)
avidity antibody The sum total of the functional binding strength between a polyvariant and its antibody. The total binding strength represents the sum strength of all the affinity bonds.
(05 Mar 2000)
binding sites, antibody Local surface sites on antibodies which react with antigen determinant sites on antigens. They are formed from parts of the variable regions of the fab fragment of the immunoglobulin.
(12 Dec 1998)
bivalent antibody Antibody that causes a visible reaction with specific antigen as in agglutination, precipitation, and so on; so-called because according to the "lattice theory" aggregation occurs when the antibody molecule has two or more binding sites that can crosslink one antigen particle to another; probably a characteristic of the class of immunoglobulin.
(05 Mar 2000)
blocking antibody An antibody used in a reaction to prevent some other reaction taking place, for example one antibody competing with another for a cell surface receptor.
See: desensitisation.
(18 Nov 1997)
reaginic antibody <immunology> A type of antibody which is able to attach itself to the surfaces of cells without needing specific combining sites. A homocytotropic antibody will only bind to cells which are from the same species as itself.
(09 Oct 1997)
maternal antibody Any antibody transferred from a mammalian mother transplacentally into the foetus. See under immunoglobulin for details of the classes of Ig that are transferred to the foetus.
(18 Nov 1997)
catalytic antibody <chemistry> Antibody raised against a transition state analogue (e.g. A phosphate analogue of a carboxylic acid ester transition state) that can then catalyse the analogous chemical reaction, though not as effectively as a true enzyme.
(16 Mar 1998)
Vi antibody A form of antibody that agglutinates highly virulent strains of Salmonella typhi, i.e., cells with Vi antigen; such bacteria are not agglutinable with O antiserum until the Vi antigen is destroyed.
See: Vi antigen.
(05 Mar 2000)
cell-bound antibody A term used for antibody on the surface of cells that may be bound either through antigen combining sites or other sites such as the Fc region.
(05 Mar 2000)
CF antibody Antibody that combines with and sensitises antigen leading to the activation of complement, which may result in cell lysis.
Synonym: CF antibody, sensitizing substance.
(05 Mar 2000)
chimeric antibody <immunology> An antibody that contains polypeptides from different species.
(05 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á